INHIBITION OF HUMAN HEPATIC GLUCURONOSYL TRANSFERASE (GT) ACTIVITY TO ALTER ZIDOVUDINE (AZT) METABOLISM (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

INHIBITION OF HUMAN HEPATIC GLUCURONOSYL TRANSFERASE (GT) ACTIVITY TO ALTER ZIDOVUDINE (AZT) METABOLISM (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 33:A2389 1992. Unique Identifier : AIDSLINE ICDB/92685725
Agrawal KC; DiPiazza NJ; Aggarwal SK; Dept. of Pharmacology, Tulane Univ. Sch. of Medicine, New; Orleans, LA 70112

Abstract: Glucuronidation (GN) is a major metabolic inactivation pathway for AZT. Inhibition of GN may improve bioavailability and prolong elimination half-life of AZT. We synthesized a series of prodrugs of AZT containing UDP-GT substrates, such as probenecid, valproic acid, salicylic acid and o-aminobenzoic acid. It was expected that after enzymatic hydrolysis, the promoiety in hepatic cells may competitively block GN of AZT. However, the concentrations of the released promoiety were insignificant to cause alteration in GN rates. Addition of certain UDP-GT substrates directly to human hepatic microsomal fraction caused significant inhibition of GN. Microsomal fractions (2 mg/ml) and AZT (100 uM) were incubated in the absence or presence of various concentrations of the substrates (5 to 100 uM) at 37 C for 4 hr. AZT GN followed the Michaelis-Menton kinetics (apparent Km 2.2 mM). Valproic acid was the best competitive inhibitor of this series and at 50 uM completely blocked the GN of AZT. These results suggest that a combination of valproic acid and AZT may significantly increase bioavailability of AZT in AIDS patients.

Keywords: Anthranilic Acids/METABOLISM/*PHARMACOLOGY Binding, Competitive Biological Availability Glucuronosyltransferase/*ANTAGONISTS & INHIB Half-Life Human Kinetics Liver/ENZYMOLOGY/*METABOLISM Microsomes, Liver/DRUG EFFECTS/ENZYMOLOGY/*METABOLISM Probenecid/METABOLISM/*PHARMACOLOGY Prodrugs/*METABOLISM/PHARMACOKINETICS Salicylic Acids/METABOLISM/*PHARMACOLOGY Valproic Acid/METABOLISM/*PHARMACOLOGY Zidovudine/*METABOLISM/PHARMACOKINETICS ABSTRACT
921030
M92A1032

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .